Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...

The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking ...

We have three antibody drug conjugate molecules, two in clinical development, one in preclinical studies, that each incorporate a novel glycan-linked topoisomerase inhibitor-based payload, which are ...

Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie’s claims. Genmab notes that this is yet another lawsuit among multiple recent lawsuits filed by ...

Emerging ADC Pipeline. MacroGenics is developing two clinical and one preclinical antibody-drug conjugate (ADC) molecules that each incorporate a novel, glycan-linked topoisomerase I inhibitor (TOP1i) ...

Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed ...

Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of ...

CX-2051 is a masked EpCAM-targeting ADC armed with a topoisomerase-1 payload, specifically designed to address profound unmet need in CRC. EpCAM is highly expressed in more than 90 percent of ...